Mission Creek Capital Partners Inc. Buys New Position in Tempus AI, Inc. (NASDAQ:TEM)

Mission Creek Capital Partners Inc. purchased a new position in Tempus AI, Inc. (NASDAQ:TEM) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 47,755 shares of the company’s stock, valued at approximately $1,612,000.

A number of other institutional investors have also recently made changes to their positions in TEM. Oxford Asset Management LLP bought a new stake in shares of Tempus AI during the 4th quarter worth $457,000. Gilder Gagnon Howe & Co. LLC purchased a new stake in Tempus AI during the fourth quarter valued at about $775,000. HBK Investments L P bought a new stake in Tempus AI during the fourth quarter worth about $5,064,000. Nebula Research & Development LLC purchased a new position in shares of Tempus AI in the 4th quarter worth about $451,000. Finally, Stifel Financial Corp increased its position in shares of Tempus AI by 935.1% during the 4th quarter. Stifel Financial Corp now owns 39,810 shares of the company’s stock valued at $1,344,000 after purchasing an additional 35,964 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Insider Activity at Tempus AI

In other news, CAO Ryan M. Bartolucci sold 13,770 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the transaction, the chief accounting officer now owns 57,237 shares in the company, valued at $3,434,220. This trade represents a 19.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Wayne A.I. Frederick sold 3,000 shares of the company’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $45.54, for a total value of $136,620.00. Following the completion of the sale, the director now directly owns 26,514 shares in the company, valued at approximately $1,207,447.56. The trade was a 10.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,584,252 shares of company stock worth $272,870,580 over the last quarter. Corporate insiders own 27.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on TEM. Bank of America upped their target price on Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. cut shares of Tempus AI from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $50.00 to $55.00 in a research note on Tuesday, February 25th. Needham & Company LLC reiterated a “buy” rating and issued a $70.00 target price on shares of Tempus AI in a research report on Thursday. TD Cowen restated a “buy” rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Finally, Loop Capital decreased their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $61.08.

Tempus AI Price Performance

Shares of TEM stock opened at $52.90 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business’s 50 day moving average price is $49.92 and its 200-day moving average price is $50.45. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.